---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-144604"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:01:13.394511+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending

## Summary
- Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
- Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.
- Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.
- Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.
- Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision.

## SEC filing metadata
- accession: 0001193125-26-144604
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/0001193125-26-144604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/d111491d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-144604
- JSON: https://secwatch.observer/filing/0001193125-26-144604.json
- Plain text: https://secwatch.observer/filing/0001193125-26-144604.txt

## Key facts
- Earnings Releases
  Jaguar Health, Inc. reported year ended December 31, 2025 results: revenue $11.5 million, net income $53.6 million net loss, EPS ($24.27) per share.
  - Period: year ended December 31, 2025
  - Revenue: $11.5 million
  - Net income: $53.6 million net loss
  - EPS: ($24.27) per share
  - Result: reported results
  source text: the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million. • In 2025, approximately $11.2 million out of the Company’s total net revenue of $11.5 million was generated by sales of Mytesi and Canalevia-CA1. Under the terms of the license agreement Jaguar entered with Future Pak (“FP”) in January 2026, FP will be responsible for all
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/0001193125-26-144604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.